CA2588088C - Derivation of embryonic stem cells - Google Patents

Derivation of embryonic stem cells Download PDF

Info

Publication number
CA2588088C
CA2588088C CA2588088A CA2588088A CA2588088C CA 2588088 C CA2588088 C CA 2588088C CA 2588088 A CA2588088 A CA 2588088A CA 2588088 A CA2588088 A CA 2588088A CA 2588088 C CA2588088 C CA 2588088C
Authority
CA
Canada
Prior art keywords
blastomere
cells
cell
embryo
culturing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2588088A
Other languages
English (en)
French (fr)
Other versions
CA2588088A1 (en
Inventor
Young Chung
Robert Lanza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Institute for Regenerative Medicine
Original Assignee
Astellas Institute for Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Institute for Regenerative Medicine filed Critical Astellas Institute for Regenerative Medicine
Priority to CA3015835A priority Critical patent/CA3015835A1/en
Publication of CA2588088A1 publication Critical patent/CA2588088A1/en
Application granted granted Critical
Publication of CA2588088C publication Critical patent/CA2588088C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
CA2588088A 2004-11-04 2005-11-04 Derivation of embryonic stem cells Expired - Lifetime CA2588088C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3015835A CA3015835A1 (en) 2004-11-04 2005-11-04 Derivation of embryonic stem cells

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US62482704P 2004-11-04 2004-11-04
US60/624,827 2004-11-04
US66248905P 2005-03-15 2005-03-15
US60/662,489 2005-03-15
US68715805P 2005-06-03 2005-06-03
US60/687,158 2005-06-03
US72306605P 2005-10-03 2005-10-03
US60/723,066 2005-10-03
US72677505P 2005-10-14 2005-10-14
US60/726,775 2005-10-14
PCT/US2005/039776 WO2006052646A2 (en) 2004-11-04 2005-11-04 Derivation of embryonic stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3015835A Division CA3015835A1 (en) 2004-11-04 2005-11-04 Derivation of embryonic stem cells

Publications (2)

Publication Number Publication Date
CA2588088A1 CA2588088A1 (en) 2006-05-18
CA2588088C true CA2588088C (en) 2018-10-09

Family

ID=36337005

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2588088A Expired - Lifetime CA2588088C (en) 2004-11-04 2005-11-04 Derivation of embryonic stem cells
CA3015835A Abandoned CA3015835A1 (en) 2004-11-04 2005-11-04 Derivation of embryonic stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3015835A Abandoned CA3015835A1 (en) 2004-11-04 2005-11-04 Derivation of embryonic stem cells

Country Status (7)

Country Link
US (4) US7838727B2 (enExample)
EP (3) EP1812554A4 (enExample)
JP (2) JP5728676B2 (enExample)
AU (1) AU2005304978A1 (enExample)
CA (2) CA2588088C (enExample)
HK (1) HK1219295A1 (enExample)
WO (1) WO2006052646A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
CA2937099A1 (en) 2004-01-23 2005-08-04 Astellas Institute For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US7622108B2 (en) 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
EP1812554A4 (en) 2004-11-04 2008-10-08 Advanced Cell Tech Inc DERIVATION OF EMBRYONAL STEM CELLS
GB0507755D0 (en) * 2005-04-16 2005-05-25 Univ Sheffield Cytotrophoblast stem cells
ES2933478T3 (es) 2005-08-03 2023-02-09 Astellas Inst For Regenerative Medicine Métodos mejorados de reprogramación de células somáticas animales
CA2646491A1 (en) * 2006-04-17 2007-10-25 Bioe, Inc. Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
EP2029724A4 (en) * 2006-05-03 2010-03-24 Advanced Cell Tech Inc DERIVATION FROM EMBRYONAL STEM CELLS AND EMBRYO-DERIVED CELLS
US20070298496A1 (en) * 2006-06-23 2007-12-27 Hung-Chih Kuo Method of deriving pluripotent stem cells from a single blastomere
KR20100014504A (ko) 2007-02-23 2010-02-10 어드밴스드 셀 테크놀로지, 인코포레이티드 분화된 세포를 리프로그래밍하고, 리프로그래밍된 세포로부터 동물 및 배아 줄기세포를 생성시키기 위한 고도로 효율적인 방법
EP2209888B1 (en) 2007-10-12 2019-12-04 Astellas Institute for Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
AU2008329563A1 (en) * 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving Oct4 protein
EP2100954A1 (en) * 2008-03-10 2009-09-16 Assistance Publique - Hopitaux de Paris Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications
JP2009225675A (ja) * 2008-03-19 2009-10-08 Tohoku Univ 上皮系細胞シートの作製のための同種皮膚由来フィーダー細胞
WO2010008054A1 (ja) 2008-07-16 2010-01-21 ディナベック株式会社 染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法
CA2772619C (en) * 2009-09-04 2019-07-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for enhancing genome stability and telomere elongation in embryonic stem cells
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
AU2011279250B2 (en) 2010-07-12 2014-12-04 California Institute Of Technology Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
EP3875599B1 (en) * 2010-07-23 2024-12-11 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US20130149287A1 (en) * 2010-07-30 2013-06-13 Cambridge Enterprise Limited Corticogenesis of Human Pluripotent Cells
WO2012149468A2 (en) 2011-04-29 2012-11-01 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
US20130142762A1 (en) * 2011-11-07 2013-06-06 Hina W. Chaudhry Methods of cardiac repair
IL287381B2 (en) 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
AU2014363032A1 (en) 2013-12-11 2016-06-09 Pfizer Limited Method for producing retinal pigment epithelial cells
WO2016005985A2 (en) 2014-07-09 2016-01-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reprogramming cells
WO2016044271A2 (en) 2014-09-15 2016-03-24 Children's Medical Center Corporation Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
EP3869195B1 (en) 2015-03-23 2024-03-20 Astellas Institute for Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
EP3823663A4 (en) 2018-07-19 2022-03-09 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR GENERATING A PHYSIOLOGICAL X-CHROMOSOME INACTIVATION
AU2020374884A1 (en) 2019-10-30 2022-06-09 Astellas Institute For Regenerative Medicine Methods for producing retinal pigment epithelium cells
AU2022270611A1 (en) 2021-05-03 2023-10-12 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
CA3217861A1 (en) 2021-05-07 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature hepatocytes
WO2022264132A1 (en) 2021-06-13 2022-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reprogramming human cells

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274705B1 (en) * 1996-05-02 2001-08-14 Aventis Pharmaceuticals Products Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
WO1995016770A1 (en) * 1993-12-17 1995-06-22 Abs Global, Inc. Ungulate preblastocyst derived embryonic stem cells and use thereof to produce cloned transgenic and chimeric ungulates
WO1995017500A1 (en) * 1993-12-23 1995-06-29 Abs Global, Inc. Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US20040199935A1 (en) 1999-06-30 2004-10-07 Chapman Karen B. Cytoplasmic transfer to de-differentiate recipient cells
JP2003512052A (ja) 1999-10-15 2003-04-02 アドバンスド セル テクノロジー、インコーポレイテッド 分化前駆細胞及び系統欠失胚性幹細胞の産生方法
JP2004500066A (ja) 1999-12-20 2004-01-08 ユニバシティ　オブ　マサチューセッツ、ア　パブリック　インスチチユーション　オブ　ハイアー　エデュケイション　オブ　ザ　コモンウエルス　オブ　マサチューセッツ、アズ　リプリゼンテッド　バイ　イッツ　ア 異種間核移植により生成する胚あるいは幹様細胞
JP2003533976A (ja) 2000-01-07 2003-11-18 オレゴン ヘルス アンド サイエンス ユニバーシティ 胚分割による霊長類子孫のクローン性増殖
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10108412B4 (de) 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
US20030082598A1 (en) 2001-08-22 2003-05-01 Ecker David J. Molecular interaction sites of 23S ribosomal RNA and methods of modulating the same
US20030224345A1 (en) 2001-08-24 2003-12-04 Advanced Cell Technology Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy
US7247477B2 (en) * 2002-04-16 2007-07-24 Technion Research & Development Foundation Ltd. Methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
US6699771B1 (en) * 2002-08-06 2004-03-02 Texas Instruments Incorporated Process for optimizing junctions formed by solid phase epitaxy
WO2004052079A2 (en) * 2002-12-10 2004-06-24 The Wistar Institute Method for programmed differentiation of stem cells
US20050118713A1 (en) 2003-05-12 2005-06-02 Nikolai Strelchenko Morula derived embryonic stem cells
US20040229350A1 (en) * 2003-05-12 2004-11-18 Nikolai Strelchenko Morula derived embryonic stem cells
TW200521236A (en) 2003-12-22 2005-07-01 Animal Technology Inst Taiwan Method for generating non-human mammalian chimeric embryo
CA2937099A1 (en) 2004-01-23 2005-08-04 Astellas Institute For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
WO2005080551A2 (en) 2004-02-12 2005-09-01 University Of Newcastle Upon Tyne Stem cells
WO2006013519A1 (en) 2004-07-26 2006-02-09 Koninklijke Philips Electronics N.V. Method of storing data in an information carrier, system for reading such an information carrier.
US20080262321A1 (en) 2004-08-06 2008-10-23 Ramot At Tel Aviv University Ltd. Early Detection of Harmful Agents: Method, System and Kit
EP1812554A4 (en) 2004-11-04 2008-10-08 Advanced Cell Tech Inc DERIVATION OF EMBRYONAL STEM CELLS
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
US7818929B2 (en) * 2004-12-14 2010-10-26 Anthony Hardwood Composites, Inc. Laminated support mat
CN101331500B (zh) * 2005-10-14 2015-04-29 尤尼森斯繁殖技术公司 细胞群的变化的测定
US20070254309A1 (en) * 2006-04-20 2007-11-01 Northern Sydney And Central Coast Area Health Service Methods for Assessing Embryo Viability
EP2029724A4 (en) * 2006-05-03 2010-03-24 Advanced Cell Tech Inc DERIVATION FROM EMBRYONAL STEM CELLS AND EMBRYO-DERIVED CELLS
US20070298496A1 (en) 2006-06-23 2007-12-27 Hung-Chih Kuo Method of deriving pluripotent stem cells from a single blastomere
KR20100014504A (ko) 2007-02-23 2010-02-10 어드밴스드 셀 테크놀로지, 인코포레이티드 분화된 세포를 리프로그래밍하고, 리프로그래밍된 세포로부터 동물 및 배아 줄기세포를 생성시키기 위한 고도로 효율적인 방법
SG172965A1 (en) * 2009-01-13 2011-08-29 Fluidigm Corp Single-cell nucleic acid analysis
EP2811016B1 (en) * 2011-05-31 2017-10-04 Unisense Fertilitech A/S Embryo quality assessment based on blastomere cleavage and morphology

Also Published As

Publication number Publication date
WO2006052646A2 (en) 2006-05-18
HK1219295A1 (en) 2017-03-31
WO2006052646A3 (en) 2006-09-28
CA2588088A1 (en) 2006-05-18
EP2479256A1 (en) 2012-07-25
US9550974B2 (en) 2017-01-24
CA3015835A1 (en) 2006-05-18
JP5728676B2 (ja) 2015-06-03
EP1812554A2 (en) 2007-08-01
JP2008518616A (ja) 2008-06-05
US20110150842A1 (en) 2011-06-23
US20060206953A1 (en) 2006-09-14
JP5841926B2 (ja) 2016-01-13
US20170204368A1 (en) 2017-07-20
US7838727B2 (en) 2010-11-23
EP2960328A1 (en) 2015-12-30
JP2013046623A (ja) 2013-03-07
US8642328B2 (en) 2014-02-04
US20140377865A1 (en) 2014-12-25
EP1812554A4 (en) 2008-10-08
AU2005304978A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
US9550974B2 (en) Derivation of embryonic stem cells
James et al. Contribution of human embryonic stem cells to mouse blastocysts
Baharvand et al. Culture condition difference for establishment of new embryonic stem cell lines from the C57BL/6 and BALB/c mouse strains
US20030113910A1 (en) Pluripotent stem cells derived without the use of embryos or fetal tissue
CN101679942A (zh) 重编程分化细胞和从重编程的细胞产生动物和胚胎干细胞的高效方法
US20070298496A1 (en) Method of deriving pluripotent stem cells from a single blastomere
KR101680269B1 (ko) 배아 줄기 세포주 및 이의 제조방법
KR101538089B1 (ko) 배아줄기세포-유사 세포
KR101213691B1 (ko) 전강 난포-유래 배아 줄기 세포
AU2016204892A1 (en) Derivation of Embryonic Stem Cells
TWI392736B (zh) 由單一分裂球取得多能幹細胞之方法
WO2006083133A2 (en) Human embryonic stem cell created from an oocyte and a somatic cell derived from non-identical individuals and a method for preparing the same
Takeuchi et al. Harvesting of embryonic stem cells aimed at embryo conservation
US20090305404A1 (en) Methods and compositions relating to blastomere-derived human embryonic stem cells
Eiges et al. Human embryonic stem cells
Ying Using Mouse Embryonic Fibroblast (MEF) as Feeder Cells for Production of Embryonic Stem Cell (ESC) Line in the Murine and Caprine
Davies et al. Embryonic stem cells and the capture of pluripotency
WO2008115087A1 (en) Process for providing embryonic stem cells
AU2013205483A1 (en) Parthenogenic activation of human oocytes for the production of human embryonic stem cells

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025